Technical analysis video on NASDAQ’s biotech penny stock OXiGENE Inc. (OXGN) Please Note: OXiGENE’s ZYBRESTAT targeted multi-billion markets for non-small cell lung and ovarian cancer, and also it is developing for the treatment of ophthalmological diseases and conditions such as the wet form of age-related macular degeneration (ARMD) and polypoidal choroidal neovascularization (PCV).
DARA BioSciences, Inc. (DARA) stock posted today 20.95% in gains on 6,424,094 shares in trading volume and brought to followers for about 55% in profits since our alert issued on September 13th. Our “gut feeling” and quick observation of DARA’s financials “told” us that a second offering for this biotech penny markets most likely is […]
OXiGENE, Inc. (OXGN) stock traded 8fold of it 10day average volume and posted 36% gains as of 1 p.m. EST. Rumor of potential buyout or partnership is circulating on investor message boards and chat rooms after that company released 8-K filings: On October 13, 2011, OXiGENE, Inc. (the “Company”) notified Kingsbridge Capital Limited (“Kingsbridge”) of […]
OXiGENE, Inc. (OXGN) announced restructuring of its clinical programs & new focus of the company: Phase 3 registrational study of ZYBRESTAT in patients with anaplastic thyroid cancer & Phase 2 ZYBRESTAT trial in non-small cell lung cancer have been put on hold. Investigator-sponsored Phase 1 trial of OXi4503 in patients with AML or myelodysplastic syndrome […]